brivaracetam News - LARVOL Sigma

«1 2 3 4 5 6 7 8 9 101112 13 »

|||||||||| Briviact (brivaracetam) / UCB
Baseline Seizure Related Disability Assessment Scale (SERDAS) Scores in an Observational Study of Brivaracetam () - Jan 21, 2020 - Abstract #AAN2020AAN_1229;
Baseline scores suggest many more days lost to seizures/seizure-related problems compared to medication side effects, except in seizure free patients, who lost more days to side effects. BRV treatment was associated with the largest reduction in seizure-related disability on this novel scale.

|||||||||| Briviact (brivaracetam) / UCB
Long-term Retention on Adjunctive Brivaracetam and Reasons for Discontinuation by Number of Lifetime AEDs in Adults With Focal Seizures: a Post hoc Analysis () - Jan 21, 2020 - Abstract #AAN2020AAN_1228;
P3
BRV treatment was associated with the largest reduction in seizure-related disability on this novel scale. Adults with focal seizures exposed to fewer AEDs before adjunctive BRV initiation had higher 1- and 3-year retention rates and were less likely to discontinue long-term BRV treatment due to lack of efficacy or adverse events.

|||||||||| Review, Journal: Novel drugs and early polypharmacotherapy in status epilepticus. (Pubmed Central) - Dec 21, 2019
Adults with focal seizures exposed to fewer AEDs before adjunctive BRV initiation had higher 1- and 3-year retention rates and were less likely to discontinue long-term BRV treatment due to lack of efficacy or adverse events. Novel drugs and strategies target the underlying pathophysiology of SE with the intent to improve seizure control and outcomes.

|||||||||| pregabalin / Generic mfg., Trileptal (oxcarbazepine) / Novartis
Journal: Update on Antiepileptic Drugs 2019. (Pubmed Central) - Dec 20, 2019
Novel drugs and strategies target the underlying pathophysiology of SE with the intent to improve seizure control and outcomes. Knowledge of AED pharmacokinetics, efficacy, and tolerability profiles facilitates the choice of appropriate AED therapy for patients with epilepsy.

|||||||||| Briviact (brivaracetam) / UCB
Brivaracetam Is More Effective Than Levetiracetam in the Treatment of Experimental Benzodiazepine-Refractory Status Epilepticus (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_1551;
Studies of acute neuronal injury showed strong neuroprotection in all groups treated with ketamine. Conclustions This experiment demonstrates that brivaracetam in more effective than higher-dose levetiracetam in stopping seizures in this model of RSE, and confirms that combinations of a GABAA receptor allosteric stimulator, a NMDA receptor antagonist and an antiepileptic drug are superior to monotherapy in treating RSE.

|||||||||| Briviact (brivaracetam) / UCB
EEG Biomarker Indicative for the Efficacy of Brivaracetam: A Retrospective Study (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_1548;
Nevertheless, prospective studies are needed to assess the added value of the developed EEG biomarker in a clinical setting. Funding: No funding

|||||||||| Briviact (brivaracetam) / UCB
Use of Brivaracetam in Cases of Acquired Pathologic Myoclonus (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_1512;
This may suggest the potential of an additive benefit in spite of a similar mechanism of action between levetiracetam and brivaracetam. It is unclear if this effect would be similar in the absence of levetiracetam.

|||||||||| Briviact (brivaracetam) / UCB
Brivaracetam Abolishes the Photoparoxysmal Response More Rapidly than Levetiracetam Post-i.v. Infusion in a Majority of Patients with Photosensitive Epilepsy: A Randomized, Double-Blind, Crossover Study (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_1401;
P2/3
Our preliminary results are in line with PET study findings (faster BRV brain penetration, SV2A occupancy) in volunteers and may support the use of BRV in treating acute seizure conditions. Clinical studies are needed to confirm our findings.

|||||||||| Briviact (brivaracetam) / UCB
Long-Term Tolerability and Retention of Adjunctive Brivaracetam in Children (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_1398;
P2, P3
Kaplan-Meier estimated 1- and 2-year retention was high, suggesting that BRV treatment was effective in this limited number of patients. Funding: UCB Pharma-sponsored

|||||||||| Briviact (brivaracetam) / UCB
Baseline Seizure Related Disability Assessment Scale (SERDAS) Scores in an Observational Study of Brivaracetam (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_1124;
Baseline scores suggest many more days lost to seizures/seizure-related problems compared to medication side effects, except in seizure free patients, who lost more days to side effects. SERDAS scores will be obtained at subsequent study visits, and will be compared to reported seizure and side effect outcomes.

|||||||||| Briviact (brivaracetam) / UCB
Time Course of 75%–100% Efficacy Response of Adjunctive Brivaracetam in Adults with Focal (Partial-Onset) Seizures and Secondarily Generalized Seizures: A Pooled Post-Hoc Analysis (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_855;
P3
This analysis extends prior findings of BRV efficacy in reducing seizure frequency from the first day of treatment. These findings may be particularly informative for the treatment of patients with SGS, who are at high risk of falls, injury, and mortality.

|||||||||| carbamazepine / Generic mfg.
Paradoxical Worsening of Frontal Lobe Seizures with Benzodiazepines (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_752;
Patient’s seizure medications were held, and on the third night, he was noted to have a cluster of seven nocturnal seizures prompting IV diazepam use for a total of 15mg.The patient continued to have seizures requiring additional BZDs, total of 12mg of IV lorazepam and 4mg of IV midazolam over the course of 7 – 8 hours...His ASDs were continued at home doses (brivaracetam 100mg TID, carbamazepine 600-400-400, and perampanel 18mg QHS)...At that point his clobazam was stopped and switched to zonisamide and his seizure frequency decreased to 0-1 per night...Conclustions Paradoxical worsening of frontal lobe seizures with benzodiazepine usage can occur. BZDs still remain the first line for acute seizure treatment, however additional precautions should be taken when used for sleep activated frontal lobe seizures.

|||||||||| Briviact (brivaracetam) / UCB, carbamazepine / Generic mfg., Trileptal (oxcarbazepine) / Novartis
Real-World Study of Brivaracetam in the US: An Interim Analysis (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_653;
Three patients died during the study, but none were judged to be drug-related. Conclustions This interim analysis indicates that retention on BRV (a measure of effectiveness) at 3 and 6 months is similar between patients that had previously failed LEV, LTG, OXC, and CBZ.

|||||||||| Briviact (brivaracetam) / UCB
High-Dose Brivaracetam Add-On Treatment of Refractory Epilepsy in Adults (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_646;
Adjunctive brivaracetam treatment with doses > 200 mg/day confers little benefit additional to BRV treatment with 200 mg/day. Funding: No funding

|||||||||| carbamazepine / Generic mfg.
Anti-Epileptic Drugs and Efficacy Against Focal to Bilateral Tonic-Clonic Seizures: A Systematic Review (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_642;
Conclustions In a landmark older study, control of convulsive seizures did not differ significantly between phenytoin, carbamazepine, phenobarbital and primidone, and in a second study they observed no significant difference between carbamazepine and valproate...At the moment, there are insufficient evidence to determine the superiority of any one AED over another for treatment of FBTCS. Worthy of mention is the fact that none of the studies we analyzed reported the reduction in FBTCS during sleep, which is especially relevant for the prevention of SUDEP.

|||||||||| Briviact (brivaracetam) / UCB
Prevention of Posttraumatic Epileptogenesis by Brivaracetam in the CCI Model of Traumatic Brain Injury in Rats (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_639;
Conclustions A single dose of BRV administered immediately (21 mg/kg) or 30 min (100 mg/kg) after cortical injury significantly reduced the development of both evoked and spontaneous epileptiform activity in rats. These results suggest that BRV may effectively interfere with PTE.

|||||||||| How are Newly FDA Approved Anti-Epileptic Drugs (AEDs) Being Utilized? (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_550;
Esclicarbazepine was had the lowest average of concurrent AEDs (1.4), followed by clobazam (1.9), brivaracetam (1.9) and perampanel (2.2)...The most commonly concurrent AEDs are medications which longstanding proven efficacy and low side effect and efficacy profiles (levetiracetam, lamotrigine, and lacosamide)...As more AEDs become FDA approved for epilepsy, it will be valuable to see if prescribing trends of the AEDs approved between 2010 and 2016 are altered. It would be valuable in future studies to see if these prescribing trends can be reaffirmed in larger patient cohorts.

|||||||||| First Clinical Experience with Ketocal in Mexican Pediatric Patients: Report of Two Cases. (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_540;
Results The response of both patients to the ketogenic diet was satisfactory, until now the same treatment is continued in ketosis surveillance as well as the registry of crisis number, lipid profile, and liver enzymes as well as electroencephalogram, during the use of the diet was decided to reduce topiramate to the risk of nephrocalcinosis without evidence of adverse effects related to diet. Conclustions The use of ketogenic diet has been well described for many years, however in Mexico the protocols for the administration of the diet are not well designed.The need for a multidisciplinary team of specialists is necessary as well as the monitoring of adverse effects related to diet in addition to the adjustment of antiepileptic drugs in each patient.The advantages of using Ketocal in these cases have been the absence of hypoglycemia, increased blood lipids in addition to not requiring nutrients such as calcium or magnesium in the treated patients.

|||||||||| Epidiolex (cannabidiol) / GW Pharma
The Effect of Epidiolex on Felbamate Levels in Children with Treatment Resistant Epilepsy (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_397;
Another recent case series described a potential interaction between CBD and Brivaracetam2...Other concomitant AEDs included Valproic acid (N=8), Clobazam (N=11), Topiramate (N=3), Levetiracetam (N=2), Zonisamide (N=1), and Vigabatrin (N=1)...Additionally, of the six subjects who were only taking Epidiolex and Felbamate, five (83%) exhibited decreased Felbamate levels. While the mechanism for the interaction is unknown, these findings suggest that close laboratory monitoring and potential dose adjustments may be required when patients taking felbamate are started on Epidiolex.

|||||||||| Fycompa (perampanel) / Eisai
Estimating the Budget Impact of Increased Utilization of Perampanel to Treat Adult and Pediatric Patients Diagnosed with Epilepsy (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_375;
This saving occurs in an environment with increased flexibility and options for treating patients with refractory epilepsy. These findings can be used to inform formulary decision making.

|||||||||| Briviact (brivaracetam) / UCB
Initial Clinical Impressions of Brivaracetam for Treatment of Epilepsy in the Pediatric Population (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_295;
It is possible that adverse neurobehavioral effects on LEV can predict whether or not patients will experience AEs on BRV. A larger prospective study may be necessary to determine the superiority of BRV to LEV.

|||||||||| Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB
Journal: Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. (Pubmed Central) - Nov 27, 2019
Expert opinion: PER and BRV have the potential to perform as important, broad-spectrum ASDs with significant market shares. BRV's intravenous formulation and fast penetration into the brain and PER's unique mode of action will result in the more frequent use of both drugs in status epilepticus.

|||||||||| Briviact (brivaracetam) / UCB
Journal: Brivaracetam for epilepsy. (Pubmed Central) - Nov 6, 2019
More than a third of patients with epilepsy cannot achieve freedom from seizures despite taking multiple medications. This article compares brivaracetam to levetiracetam, and provides guidelines for the safe and effective use of brivaracetam.

|||||||||| ganaxolone oral (CCD-1042) / Marinus
Journal: New antiepileptic drugs (Pubmed Central) - Nov 2, 2019
Cannabidiol and fenfluramine are useful in the treatment of Dravet or Lennox Gastaut syndrome. Allopregnenolona and ganaxolone showed good efficacy in status epilepticus and could play an important future role in this clinical scenario.

|||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial. (Pubmed Central) - Oct 31, 2019
P2
This open-label trial in pediatric patients with epilepsy provides preliminary information that short-term, adjunctive brivaracetam treatment is well tolerated and effective. Plasma concentrations of brivaracetam and metabolites increased with increasing dose.

||||||||||  brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) -  Oct 9, 2019
P3, N=10, Recruiting,  Sponsor: UCB Biopharma S.P.R.L.
Plasma concentrations of brivaracetam and metabolites increased with increasing dose. Trial completion date: Jun 2020 --> Mar 2021 | Trial primary completion date: Jun 2020 --> Mar 2021

|||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures. (Pubmed Central) - Oct 9, 2019
Trial completion date: Jun 2020 --> Mar 2021 | Trial primary completion date: Jun 2020 --> Mar 2021 Simulation with the adult brivaracetam PK/PD model in combination with an existing pediatric brivaracetam population PK model allowed characterization of the dose-response curve, suggesting maximum response at brivaracetam 4 mg/kg/day dosing (capped at 200 mg/day, the maximum adult dose) in children aged ≥4 years.

|||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: Brivaracetam in the treatment of epilepsy: a review of clinical trial data. (Pubmed Central) - Oct 3, 2019
In this setting, immediate switch from LEV to BRV at a 10:1-15:1 ratio without titration is feasible. Further research is needed to examine the long-term tolerability and efficacy of BRV as well as its role in the treatment of other types of epilepsies, particularly dementia-related epilepsy and brain tumor-related epilepsy.

|||||||||| Trileptal (oxcarbazepine) / Novartis
Clinical, PK/PD data, Review, Journal: Pharmacokinetic Considerations with the Use of Antiepileptic Drugs in Patients with HIV and Organ Transplants. (Pubmed Central) - Sep 28, 2019
Antiepileptic drugs with no or minimal enzyme-inducing properties include brivaracetam, gabapentin, lacosamide, lamotrigine, levetiracetam, perampanel, pregabalin, and vigabatrin. The newer generations of antiepileptic drugs have expanded the therapeutic options in patients with HIV infection or organ transplants.

||||||||||  brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date:  Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (clinicaltrials.gov) -  Sep 19, 2019
P3, N=600, Enrolling by invitation,  Sponsor: UCB Pharma SA
The newer generations of antiepileptic drugs have expanded the therapeutic options in patients with HIV infection or organ transplants. Trial completion date: Jan 2024 --> Jul 2022 | Trial primary completion date: Dec 2023 --> Jul 2022

|||||||||| Briviact (brivaracetam) / UCB
Clinical, Review, Journal: Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. (Pubmed Central) - Sep 17, 2019
BRV has been recently introduced as an adjunct antiepileptic drug in focal epilepsy with a similarly promising pharmacokinetic profile and possibly increased tolerability concerning psychiatric adverse events. This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center.

||||||||||  brivaracetam / Generic mfg.
Trial completion:  Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy (clinicaltrials.gov) -  Sep 17, 2019
P3, N=853, Completed,  Sponsor: UCB Pharma
This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center. Active, not recruiting --> Completed

||||||||||  brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date:  A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) -  Sep 16, 2019
P2, N=50, Recruiting,  Sponsor: UCB Biopharma S.P.R.L.
Active, not recruiting --> Completed Trial completion date: Jul 2020 --> Apr 2020 | Trial primary completion date: Jul 2020 --> Apr 2020

||||||||||  brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date:  A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy (clinicaltrials.gov) -  Sep 6, 2019
P3, N=504, Recruiting,  Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Jul 2020 --> Apr 2020 | Trial primary completion date: Jul 2020 --> Apr 2020 Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Jul 2022

||||||||||  brivaracetam / Generic mfg.
Enrollment closed:  BASE: Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (clinicaltrials.gov) -  Sep 6, 2019
P=N/A, N=551, Active, not recruiting,  Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Jul 2022 Recruiting --> Active, not recruiting

||||||||||  brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date:  A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) -  Sep 6, 2019
P3, N=227, Enrolling by invitation,  Sponsor: UCB Biopharma S.P.R.L.
Recruiting --> Active, not recruiting Trial completion date: May 2024 --> Feb 2025 | Trial primary completion date: May 2024 --> Feb 2025

|||||||||| Briviact (brivaracetam) / UCB
Journal: Recent anti-seizure medications in the intensive care unit. (Pubmed Central) - Jul 26, 2019
Recent ASMs and could represent better treatment choices in critically ill patients than older ones but this needs to be confirmed in randomized controlled studies. In general, further studies are required to clarify the indications and optimal use of ASMs in the critical care setting.

|||||||||| Briviact (brivaracetam) / UCB, Belviq (lorcaserin) / Eisai, Belsomra (suvorexant) / Merck (MSD)
Journal: Simultaneous Detection and Quantification of Three Novel Prescription Drugs of Abuse (Suvorexant, Lorcaserin and Brivaracetam) in Human Plasma by UPLC-MS-MS. (Pubmed Central) - Jul 24, 2019
The limit of detection values for SVR, LCR and BVR were 0.08, 0.11 and 0.26 ng/mL, respectively, whereas the limit of quantification values were 0.16, 0.27 and 0.65 ng/mL, respectively. The assay developed in this study is suitable for the identification and quantification of SVR, LCR and BVR in the forensic laboratory.

|||||||||| Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB, Aptiom (eslicarbazepine) / Sumitomo Dainippon, Eisai
Journal: Safety profile of the newest antiepileptic drugs: a curated literature review. (Pubmed Central) - Jul 11, 2019
The assay developed in this study is suitable for the identification and quantification of SVR, LCR and BVR in the forensic laboratory. Early detection of ADRs could lead to an improvement in patients' quality of life, therefore it is important to monitor ADRs and to adequately perform post marketing surveillance in the clinical practice setting.

|||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities. (Pubmed Central) - Jul 11, 2019
A total of 91.6% had received levetiracetam (LEV) before, in whom LEV was discontinued because of psychiatric adverse events (PAEs) in half. Seventy-seven percent of patients who developed PAEs with LEV did not do so on BRV suggesting that BRV is better tolerated than LEV in complex patients with psychiatric comorbidities and that the synaptic vesicle glycoprotein 2A (SV2A) protein modulation is unlikely to be implicated in LEV-related PAEs.

|||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: Letter re: Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. (Pubmed Central) - Jul 1, 2019
Seventy-seven percent of patients who developed PAEs with LEV did not do so on BRV suggesting that BRV is better tolerated than LEV in complex patients with psychiatric comorbidities and that the synaptic vesicle glycoprotein 2A (SV2A) protein modulation is unlikely to be implicated in LEV-related PAEs. No abstract available

||||||||||  brivaracetam / Generic mfg.
Enrollment change:  A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting (clinicaltrials.gov) -  Jun 26, 2019
P2, N=46, Completed,  Sponsor: UCB Biopharma S.P.R.L.
No abstract available N=110 --> 46

|||||||||| Briviact (brivaracetam) / UCB
P3 data, Journal, Adverse events: Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials. (Pubmed Central) - Jun 22, 2019
Due to their clinical relevance and impact on quality of life, new trials should make data related to the prevalence and discontinuation rates of these side effects publicly available. Given the clear dose response effect, physicians should consider aiming for lower drug loads and adjusting doses to improve tolerability.

|||||||||| Briviact (brivaracetam) / UCB
Clinical, P4 data, Retrospective data, Journal: Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. (Pubmed Central) - Jun 15, 2019
An immediate switch from LEV to BRV at a ratio of 10:1 is feasible. The occurrence of psychobehavioral adverse events seems less prominent than under LEV and a switch to BRV can be considered in patients with LEV-induced adverse events.

|||||||||| Briviact (brivaracetam) / UCB
Let's throw brivaracetam in the mix- I don't love lev as it doesn't seem to get there- @AbdallaTweet has an upcoming pub with brev in RSE. But I agree with y'all on either aforementioned options provided doses optimized. Also looking forward to ESETT any min now (Twitter) - Jun 13, 2019

||||||||||  padsevonil (UCB0942) / UCB
Trial completion:  A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil (clinicaltrials.gov) -  Jun 13, 2019
P1, N=28, Completed,  Sponsor: UCB Biopharma S.P.R.L.
The occurrence of psychobehavioral adverse events seems less prominent than under LEV and a switch to BRV can be considered in patients with LEV-induced adverse events. Recruiting --> Completed

|||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response. (Pubmed Central) - Jun 7, 2019
BRV concentrations performed outside the frame of a standardised protocol merely ascertain BRV administration. This study is however limited by its small sample size.

||||||||||  brivaracetam / Generic mfg.
Enrollment open:  A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (clinicaltrials.gov) -  May 14, 2019
P2/3, N=42, Recruiting,  Sponsor: UCB Biopharma S.P.R.L.
This study is however limited by its small sample size. Not yet recruiting --> Recruiting

|||||||||| Briviact (brivaracetam) / UCB
Retrospective data, Journal: BRIVA-LIFE - a multicentre retrospective study of the long-term use of brivaracetam in clinical practice. (Pubmed Central) - May 9, 2019
Not yet recruiting --> Recruiting In a large population of patients with predominantly drug-resistant epilepsy, brivaracetam was effective and well-tolerated; no unexpected AEs occurred over 1 year, and the incidence of PAEs was lower compared with levetiracetam.

|||||||||| Trileptal (oxcarbazepine) / Novartis
Journal: Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. (Pubmed Central) - Apr 30, 2019
For the older first generation AEDs (carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone and valproic acid), much data has accumulated in this regard. However, this is occurring increasingly for the new AEDs (brivaracetam, eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, piracetam, pregabalin, rufinamide, stiripentol, sulthiame, tiagabine, topiramate, vigabatrin and zonisamide).



	Diseases Companies Products Productz Mechanisms of Action Sites